Type-2 cannabinoid receptors in neurodegeneration

Pharmacological Research

Volumn 111, Issue , 2016, Pages 721-730

  Bisogno, Tiziana ^a,b   Oddi, Sergio ^c,d   Piccoli, Alessandra ^b   Fazio, Domenico ^b   Maccarrone, Mauro ^b,d  

^a CNR   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^c UNIVERSITY OF TERAMO   (Italy)

^d IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

Endocannabinoid system; Neurodegeneration; Type 2 cannabinoid receptors

Indexed keywords

CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; ENDOCANNABINOID; NEUROPROTECTIVE AGENT;

ALZHEIMER DISEASE; ARTICLE; BRAIN INJURY; HUMAN; HUNTINGTON CHOREA; MOLECULAR PATHOLOGY; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; SPINAL CORD INJURY; AGONISTS; ANIMAL; BRAIN; DEGENERATIVE DISEASE; DRUG EFFECTS; METABOLISM; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY; SPINAL CORD;

ANIMALS; BRAIN; CANNABINOID RECEPTOR AGONISTS; ENDOCANNABINOIDS; HUMANS; NERVE DEGENERATION; NEURODEGENERATIVE DISEASES; NEURONS; NEUROPROTECTIVE AGENTS; RECEPTOR, CANNABINOID, CB2; SIGNAL TRANSDUCTION; SPINAL CORD;

EID: 84979937169     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.07.021     Document Type: Article

References (117)

1. [1] Maccarrone, M., Bab, I., Bíró, T., Cabral, G.A., Dey, S.K., Di Marzo, V., Konje, J.C., Kunos, G., Mechoulam, R., Pacher, P., Sharkey, K.A., Zimmer, A., Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol. Sci. 36 (2015), 1–20.
2. [2] Maccarrone, M., Dainese, E., Oddi, S., Intracellular trafficking of anandamide: new concepts for signaling. Trends Biochem. Sci. 35 (2010), 601–618.
3. [3] Fezza, F., Bari, M., Florio, R., Talamonti, E., Feole, M., Maccarrone, M., Endocannabinoids, related compounds and their metabolic routes. Molecules 19 (2014), 17078–17106.
4. [4] Lu, H.C., Mackie, K., An introduction to the endogenous cannabinoid system. Biol. Psychiatry 79 (2016), 516–525.
5. [5] Chevaleyre, V., Takahashi, K.A., Castillo, P.E., Endocannabinoid-mediated synaptic plasticity in the CNS. Annu. Rev. Neurosci. 29 (2006), 37–76.
6. [6] Paradisi, A., Oddi, S., Maccarrone, M., The endocannabinoid system in ageing: a new target for drug development. Curr. Drug Targets 7 (2006), 1539–1552.
7. [7] Mechoulam, R., Parker, L.A., The endocannabinoid system and the brain. Annu. Rev. Psychol. 64 (2013), 21–47.
8. [8] Bonnet, A.E., Marchalant, Y., Potential therapeutical contributions of the endocannabinoid system towards aging and Alzheimer's disease. Aging Dis. 1 (2015), 400–405.
9. 2 receptor: a new target for controlling neural cell survival?. Trends Pharmacol. Sci. 28 (2007), 39–45.
10. 2 receptor agonism protects central neurons from remote axotomy-induced apoptosis through the PI3K/Akt pathway. J. Neurosci. 29 (2009), 4564–4570.
11. [11] Bisogno, T., Di Marzo, V., Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders. CNS Neurol. Disord. Drug Targets 9 (2010), 564–573.
12. [12] Fernández-Ruiz, J., Hernández, M., Ramos, J.A., Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders. CNS Neurosci. Ther. 16 (2010), e72–91.
13. [13] Fernández-Ruiz, J., Moro, M.A., Martínez-Orgado, J., Cannabinoids in neurodegenerative disorders and stroke/brain trauma: from preclinical models to clinical applications. Neurotherapeutics 12 (2015), 793–806.
14. [14] Pryce, G., Riddall, D.R., Selwood, D.L., Giovannoni, G., Baker, D., Neuroprotection in experimental autoimmune encephalomyelitis and progressive multiple sclerosis by cannabis-based cannabinoids. J. Neuroimmune Pharmacol. 10 (2015), 281–292.
15. [15] Bedse, G., Romano, A., Lavecchia, A.M., Cassano, T., Gaetani, S., The role of endocannabinoid signaling in the molecular mechanisms of neurodegeneration in Alzheimer's disease. J. Alzheimers Dis. 43 (2015), 1115–1136.
16. [16] Iannotti, F.A., Di Marzo, V., Petrosino, S., Endocannabinoids and endocannabinoid-related mediators: targets, metabolism and role in neurological disorders. Prog. Lipid Res. 62 (2016), 107–128.
17. [17] Klein, T.W., Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat. Rev. Immunol. 5 (2005), 400–411.
18. [18] Chiurchiù, V., Battistini, L., Maccarrone, M., Endocannabinoid signaling in innate and adaptive immunity. Immunology 144 (2015), 352–364.
19. [19] Munro, S., Thomas, K.L., Abu-Shaar, M., Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 (1993), 61–65.
20. 2: a cannabinoid receptor with an identity crisis. Br. J. Pharmacol. 160 (2010), 467–479.
21. 2). Semin. Immunol. 26 (2014), 369–379.
22. 2 receptors in brain. Ann. N. Y. Acad. Sci. 1074 (2006), 514–536.
23. 2 cannabinoid receptor mRNAs in the mouse hippocampus. Neuroscience 311 (2015), 253–267.
24. 2 receptors in a mouse model of Aβ amyloidosis: immunohistochemical analysis and suitability as a PET biomarker of neuroinflammation. PLoS One, 10, 2015, e0129618.
25. [25] Howlett, A.C., Cannabinoid receptor signaling. Handb. Exp. Pharmacol. 168 (2005), 53–79.
26. 2 receptor agonists. Chem. Rev. 116 (2016), 519–560.
27. [27] den Boon, F.S., Chameau, P., Schaafsma-Zhao, Q., van Aken, W., Bari, M., Oddi, S., Kruse, C.G., Maccarrone, M., Wadman, W.J., Werkman, T.R., Excitability of prefrontal cortical pyramidal neurons is modulated by activation of intracellular type-2 cannabinoid receptors. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 3534–3539.
28. [28] den Boon, F.S., Chameau, P., Houthuijs, K., Bolijn, S., Mastrangelo, N., Kruse, C.G., Maccarrone, M., Wadman, W.J., Werkman, T.R., Endocannabinoids produced upon action potential firing evoke a Cl(−) current via type-2 cannabinoid receptors in the medial prefrontal cortex. Pflugers Arch. 466 (2014), 2257–2268.
29. 2 receptor in remote delayed neurodegeneration. J. Mol. Med. 90 (2012), 371–387.
30. [30] Smith, S.R., Terminelli, C., Denhardt, G., Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice. J. Pharmacol. Exp. Ther. 293 (2000), 136–150.
31. [31] Molina-Holgado, F., Pinteaux, E., Moore, J.D., Molina-Holgado, E., Guaza, C., Gibson, R.M., Rothwell, N.J., Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. J. Neurosci. 23 (2003), 6470–6474.
32. [32] Franklin, A., Parmentier-Batteur, S., Walter, L., Greenberg, D.A., Stella, N., Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility. J. Neurosci. 23 (2003), 7767–7775.
33. [33] Reilly, P., The impact of neurotrauma on society: an international perspective. Prog. Brain Res. 161 (2007), 3–9.
34. [34] Graham, D.I., Clark, J.C., Adam, J.H., Gennarelli, T.A., Diffuse axonal injury caused by assault. J. Clin. Pathol. 45 (1992), 840–841.
35. [35] Graham, D.I., Gentleman, S.M., Nicoll, J.A., Royston, M.C., McKenzie, J.E., Roberts, G.W., Griffin, W.S., Altered beta-APP metabolism after head injury and its relationship to the aetiology of Alzheimer's disease. Acta Neurochir. Suppl. 66 (1996), 96–102.
36. [36] McIntosh, T.K., Smith, D.H., Meaney, D.F., Kotapka, M.J., Gennarelli, T.A., Graham, D.I., Neuropathological sequelae of traumatic brain injury: relationship to neurochemical and biomechanical mechanisms. Lab. Invest. 74 (1996), 315–342.
37. [37] Block, F., Dihné, M., Loos, M., Inflammation in areas of remote changes following focal brain lesion. Prog. Neurobiol. 75 (2005), 342–365.
38. [38] Binkofski, F., Seitz, R.J., Arnold, S., Classen, J., Benecke, R., Freund, H.J., Thalamic metabolism and corticospinal tract integrity determine motor recovery in stroke. Ann. Neurol. 39 (1996), 460–470.
39. [39] Panikashvili, D., Simeonidou, C., Ben-Shabat, S., Hanus, L., Breuer, A., Mechoulam, R., Shohami, E., An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413 (2001), 527–531.
40. [40] Baker, D., Pryce, G., Croxford, J.L., Brown, P., Pertwee, R.G., Makriyannis, A., Khanolkar, A., Layward, L., Fezza, F., Bisogno, T., Di Marzo, V., Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. 15 (2001), 300–302.
41. [41] Garcia-Ovejero, D., Arevalo-Martin, A., Petrosino, S., Docagne, F., Hagen, C., Bisogno, T., Watanabe, M., Guaza, C., Di Marzo, V., Molina-Holgado, E., The endocannabinoid system is modulated in response to spinal cord injury in rats. Neurobiol. Dis. 33 (2009), 57–71.
42. [42] Hansen, H.H., Schmid, P.C., Bittigau, P., Lastres-Becker, I., Berrendero, F., Manzanares, J., Ikonomidou, C., Schmid, H.H., Fernández-Ruiz, J.J., Hansen, H.S., Anandamide but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration. J. Neurochem. 78 (2001), 1415–1427.
43. [43] Marsicano, G., Goodenough, S., Monory, K., Hermann, H., Eder, M., Cannich, A., Azad, S.C., Cascio, M.G., Gutiérrez, S.O., van der Stelt, M., López-Rodriguez, M.L., Casanova, E., Schütz, G., Zieglgänsberger, W., Di Marzo, V., Behl, C., Lutz, B., CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302 (2003), 84–88.
44. [44] Golech, S.A., McCarron, R.M., Chen, Y., Bembry, J., Lenz, F., Mechoulam, R., Shohami, E., Spatz, M., Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors. Brain Res. Mol. Brain Res. 132 (2004), 87–92.
45. 2 cannabinoid receptors. Ann. N. Y. Acad. Sci. 1139 (2008), 450–457.
46. [46] Wotherspoon, G., Fox, A., McIntyre, P., Colley, S., Bevan, S., Winter, J., Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons. Neuroscience 135 (2005), 235–245.
47. [47] Pacher, P., Mechoulam, R., Is lipid signaling through cannabinoid 2 receptors part of a protective system?. Prog. Lipid Res. 50 (2011), 193–211.
48. [48] Elliott, M.B., Tuma, R.F., Amenta, P.S., Barbe, M.F., Jallo, J.I., Acute effects of a selective cannabinoid-2 receptor agonist on neuroinflammation in a model of traumatic brain injury. J. Neurotrauma 28 (2011), 973–981.
49. [49] Amenta, P.S., Jallo, J.I., Tuma, R.F., Elliott, M.B., A cannabinoid type 2 receptor agonist attenuates blood-brain barrier damage and neurodegeneration in a murine model of traumatic brain injury. J. Neurosci. Res. 90 (2012), 2293–2305.
50. [50] Tchantchou, F., Tucker, L.B., Fu, A.H., Bluett, R.J., McCabe, J.T., Patel, S., Zhang, Y., The fatty acid amide hydrolase inhibitor PF-3845 promotes neuronal survival, attenuates inflammation and improves functional recovery in mice with traumatic brain injury. Neuropharmacology 85 (2014), 427–439.
51. 2 cannabinoid receptor antagonists prevent minocycline-induced neuroprotection following traumatic brain injury in mice. Cereb. Cortex 25 (2015), 35–45.
52. 2 receptor activation attenuates motor and autonomic function deficits in a mouse model of spinal cord injury. Clin. Neurosurg. 55 (2008), 172–177.
53. 2 receptor yields improved attenuation of motor and autonomic deficits in a mouse model of spinal cord injury. Clin. Neurosurg. 56 (2009), 84–92.
54. [54] Adhikary, S., Li, H., Heller, J., Skarica, M., Zhang, M., Ganea, D., Tuma, R.F., Modulation of inflammatory responses by a cannabinoid-2–selective agonist after spinal cord injury. J. Neurotrauma 28 (2011), 2417–2427.
55. 2 receptors after spinal cord injury is a protective response involved in spontaneous recovery. PLoS One, 7, 2012, e49057.
56. 2 receptor (CB2R) stimulation delays rubrospinal mitochondrial-dependent degeneration and improves functional recovery after spinal cord hemisection by ERK1/2 inactivation. Cell. Death Dis., 5, 2014, e1404.
57. [57] Amenta, P.S., Jallo, J.I., Tuma, R.F., Hooper, D.C., Elliott, M.B., Cannabinoid receptor type-2 stimulation, blockade, and deletion alter the vascular inflammatory responses to traumatic brain injury. J. Neuroinflammation, 11, 2014, 191.
58. [58] Selkoe, D.J., Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81 (2001), 741–766.
59. [59] Giacobini, E., Gold, G., Alzheimer disease therapy-moving from amyloid-β to tau. Nat. Rev. Neurol. 9 (2013), 677–686.
60. [60] Rafii, M.S., Aisen, P.S., Advances in Alzheimer's disease drug development. BMC Med. 13 (2015), 62–68.
61. [61] Grünblatt, E., Zander, N., Bartl, J., Jie, L., Monoranu, C.-M., Arzberger, T., Ravid, R., Roggendorf, W., Gerlach, M., Riederer, P., Comparison analysis of gene expression patterns between sporadic Alzheimer's and Parkinson's disease. J. Alzheimers Dis. 12 (2007), 291–311.
62. 2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J. Neurosci. 23 (2003), 11136–11141.
63. [63] Ramírez, B.G., Blázquez, C., Gómez del Pulgar, T., Guzmán, M., de Ceballos, M.L., Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J. Neurosci. 23 (2005), 1904–1913.
64. 2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients. Neurobiol. Aging 34 (2013), 805–808.
65. [65] van der Stelt, M., Mazzola, C., Esposito, G., Matias, I., Petrosino, S., Filippis, D.D., Micale, V., Steardo, L., Drago, F., Iuvone, T., Di Marzo, V., Endocannabinoids and β-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels. Cell. Mol. Life Sci. CMLS 63 (2006), 1410–1424.
66. [66] Esposito, G., Iuvone, T., Savani, C., Scuderi, C., Filippis, D.D., Papa, M., Marzo, V.D., Steardo, L., Opposing control of cannabinoid receptor stimulation on amyloid-β-induced reactive gliosis: in vitro and in vivo evidence. J. Pharmacol. Exp. Ther. 322 (2007), 1144–1152.
67. 2). Bioorg. Med. Chem. 18 (2010), 5202–5207.
68. 2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in AβPP/PS1 mice. J. Alzheimers Dis. 35 (2013), 847–858.
69. 2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures. J. Neurosci. Res. 67 (2002), 829–836.
70. [70] Sheng, W.S., Hu, S., Min, X., Cabral, G.A., Lokensgard, J.R., Peterson, P.K., Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. Glia 49 (2005), 211–219.
71. 2) suppresses microglial activation. J. Neuroinflammation 2 (2005), 2–29.
72. 2 receptor-dependent mechanism. Mol. Pharmacol. 65 (2004), 999–1007.
73. [73] Walter, L., Franklin, A., Witting, A., Wade, C., Xie, Y., Kunos, G., Mackie, K., Stella, N., Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J. Neurosci. 23 (2003), 1398–1405.
74. [74] Martín-Moreno, A.M., Reigada, D., Ramírez, B.G., Mechoulam, R., Innamorato, N., Cuadrado, A., de Ceballos, M.L., Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease. Mol. Pharmacol. 79 (2011), 964–973.
75. 2 receptor system reverses amyloid-induced memory deficiency. Neurobiol. Aging 34 (2013), 791–804.
76. [76] Martín-Moreno, A.M., Brera, B., Spuch, C., Carro, E., García-García, L., Delgado, M., Pozo, M.A., Innamorato, N.G., Cuadrado, A., de Ceballos, M.L., Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 mice. J. Neuroinflammation 9 (2012), 8–12.
77. 2 receptor deficiency increases amyloid pathology and alters tau processing in a transgenic mouse model of Alzheimer's disease. Mol. Med. 19 (2014), 357–364.
78. [78] Schmöle, A.-C., Lundt, R., Ternes, S., Albayram, Ö., Ulas, T., Schultze, J.L., Bano, D., Nicotera, P., Alferink, J., Zimmer, A., Cannabinoid receptor 2 deficiency results in reduced neuroinflammation in an Alzheimer's disease mouse model. Neurobiol. Aging 36 (2015), 710–719.
79. [79] Di Marzo, V., Hill, M.P., Bisogno, T., Crossman, A.R., Brotchie, J.M., Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J. 14 (2000), 1432–1438.
80. 1 receptor mRNA levels in the caudate-putamen. Life Sci. 66 (2000), 485–494.
81. 1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. Eur. J. Neurosci. 14 (2001), 1827–1832.
82. [82] Gubellini, P., Picconi, B., Bari, M., Battista, N., Calabresi, P., Centonze, D., Bernardi, G., Finazzi-Agrò, A., Maccarrone, M., Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J. Neurosci. 22 (2002), 6900–6907.
83. [83] Pisani, A., Fezza, F., Galati, S., Battista, N., Napolitano, S., Finazzi-Agrò, A., Bernardi, G., Brusa, L., Pierantozzi, M., Stanzione, P., Maccarrone, M., High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients. Ann. Neurol. 57 (2005), 777–779.
84. [84] Fernández-Ruiz, J.J., The endocannabinoid system as a target for the treatment of motor dysfunction. Br. J. Pharmacol. 156 (2009), 1029–1040.
85. 1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism. Neurobiol. Dis. 18 (2005), 591–601.
86. 1 receptor antagonist, in a rat model of Parkinson's disease. Brain Res. 1073–1074 (2006), 209–219.
87. [87] Kelsey, J.E., Harris, O., Cassin, J., The CB(1) antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease. Behav. Brain Res., 2009, 304–307.
88. [88] McGeer, P.L., McGeer, E.G., Glial cell reactions in neurodegenerative diseases: pathophysiology and therapeutic interventions. Alzheimer Dis. Assoc. Disord. 12:Suppl. 2 (1998), S1–S6.
89. [89] Price, D.A., Martinez, A.A., Seillier, A., Koek, W., Acosta, Y., Fernandez, E., Strong, R., Lutz, B., Marsicano, G., Roberts, J.L., Giuffrida, A., WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Eur. J. Neurosci. 29 (2009), 2177–2186.
90. [90] Hoang, T., Choi, D.K., Nagai, M., Wu, D.C., Nagata, T., Prou, D., Wilson, G.L., Vila, M., Jackson-Lewis, V., Dawson, V.L., Dawson, T.M., Chesselet, M.F., Przedborski, S., Neuronal NOS and cyclooxygenase-2 contribute to DNA damage in a mouse model of Parkinson disease. Free Radic. Biol. Med. 47 (2009), 1049–1056.
91. [91] Hoban, D.B., Connaughton, E., Connaughton, C., Hogan, G., Thornton, C., Mulcahy, P., Moloney, T.C., Dowd, E., Further characterisation of the LPS model of Parkinson's disease: a comparison of intra-nigral and intra-striatal lipopolysaccharide administration on motor function, microgliosis and nigrostriatal neurodegeneration in the rat. Brain Behav. Immun. 27 (2013), 91–100.
92. 9-THCV in animal models of Parkinson's disease. Br. J. Pharmacol. 163 (2011), 1495–1506.
93. 2 receptor in neurotoxic and inflammation-driven rat models of Parkinson's disease. Exp. Neurol. 269 (2015), 133–141.
94. [94] Cicchetti, F., Brownell, A.L., Williams, K., Chen, Y.I., Livni, E., Isacson, O., Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur. J. Neurosci. 15 (2002), 991–998.
95. [95] Depino, A.M., Earl, C., Kaczmarczyk, E., Ferrari, C., Besedovsky, H., del Rey, A., Pitossi, F.J., Oertel, W.H., Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease. Eur. J. Neurosci. 18 (2003), 2731–2742.
96. [96] Walsh, S., Finn, D.P., Dowd, E., Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson's disease in the rat. Neuroscience 175 (2011), 251–261.
97. 2 receptors in human nigral neurons that degenerate in Parkinson's disease. Neurosci. Lett. 587 (2015), 1–4.
98. [98] Gómez-Gálvez, Y., Palomo-Garo, C., Fernández-Ruiz, J.J., García, C., Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 64 (2016), 200–208.
99. [99] More, S.V., Choi, D.K., Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection. Mol. Neurodegener. 10 (2015), 17–31.
100. [100] The Huntington's Disease Collaborative Research Group, A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 72 (1993), 971–983.
101. [101] Glass, M., Faull, R.L., Dragunow, M., Loss of cannabinoid receptors in the substantia nigra in Huntington's disease. Neuroscience 56 (1993), 523–527.
102. [102] Glass, M., Dragunow, M., Faull, R.L., The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 97 (2000), 505–519.
103. [103] Lastres-Becker, I., Gómez, M., De Miguel, R., Ramos, J.A., Fernández-Ruiz, J.J., Loss of cannabinoid CB(1) receptors in the basal ganglia in the late akinetic phase of rats with experimental Huntington's disease. Neurotox. Res. 4 (2002), 601–608.
104. [104] Maccarrone, M., Battista, N., Centonze, D., The endocannabinoid pathway in Huntington's disease: a comparison with other neurodegenerative diseases. Prog. Neurobiol. 81 (2007), 349–379.
105. 1 cannabinoid receptors with neuroprotective activity. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 8257–8262.
106. 2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease. Glia 57 (2009), 1154–1167.
107. 2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain 132 (2009), 3152–3164.
108. [108] Bouchard, J., Truong, J., Bouchard, K., Dunkelberger, D., Desrayaud, S., Moussaoui, S., Tabrizi, S.J., Stella, N., Muchowski, P.J., Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington's disease. J. Neurosci. 32 (2012), 18259–18268.
109. [109] Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S.W., Bates, G.P., Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87 (1996), 493–506.
110. 2 is expressed on vascular cells but not astroglial cells in the post-mortem human Huntington's disease brain. J. Chem. Neuroanat. 59–60 (2014), 62–71.
111. [111] Sagredo, O., García-Arencibia, M., de Lago, E., Finetti, S., Decio, A., Fernández-Ruiz, J., Cannabinoids and neuroprotection in basal ganglia disorders. Mol. Neurobiol. 36 (2007), 82–91.
112. [112] Sagredo, O., Pazos, M.R., Valdeolivas, S., Fernandez-Ruiz, J., Cannabinoids: novel medicines for the treatment of Huntington's disease. Recent Patents CNS Drug Discov. 7 (2012), 41–48.
113. [113] J. Fernández-Ruiz, J. Romer, J.A. Ramos, Endocannabinoids and neurodegenerative disorders: Parkinson's disease, Huntington's chorea, Alzheimer's disease and others. In: R.G. Pertwee (ed.) Handbook of Experimental Pharmacology: Endocannabinoids. Germany, Dortmund: Springer, 231, 2015, pp. 233–259.
114. [114] López-Sendón Moreno, J.L., García Caldentey, J., Trigo Cubillo, P., Ruiz Romero, C., García Ribas, G., Alonso Arias, M.A., García de Yébenes, M.J., Tolón, R.M., Galve-Roperh, I., Sagredo, O., Valdeolivas, S., Resel, E., Ortega-Gutierrez, S., García-Bermejo, M.L., Fernández Ruiz, J., Guzmán, M., García de Yébenes Prous, J., A double-blind randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease. J. Neurol. 263 (2016), 1390–1400.
115. [115] Valdeolivas, S., Navarrete, C., Cantarero, I., Bellido, M.L., Muñoz, E., Sagredo, O., Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice. Neurotherapeutics 12 (2015), 185–199.
116. [116] Arevalo-Martin, A., Garcia-Ovejero, D., Molina-Holgado, E., The endocannabinoid 2-arachidonoylglycerol reduces lesion expansion and white matter damage after spinal cord injury. Neurobiol. Dis. 38 (2010), 304–312.
117. [117] Janefjord, E., Mååg, J.L., Harvey, B.S., Smid, S.D., Cannabinoid effects on β amyloid fibril and aggregate formation, neuronal and microglial-activated neurotoxicity in vitro. Cell. Mol. Neurobiol. 34 (2014), 31–42.